Akela Pharma Inc. · Austin , TX United States (Toronto: AKL)
| 11501 Domain Dr., Ste. 130 | Phone: 512-834-0449 |
| Austin , TX | Fax: 512-834-2105 |
| 78758 | |
| United States | 
Map This Company |
Akela Pharma Inc. Rankings
Company Description
Drug developer Akela Pharma is hoping to be there before the last dose of pain meds wears off and the next dose kicks in. The company's lead product candidate is Fentanyl Taifun, an inhaled formulation of cancer pain fighter fentanyl, to be used in conjunction with other drugs to manage severe pain. Akela Pharma is also working on research in areas not related to pain relief; it is developing a growth hormone stimulator to help treat frailty and malnutrition in patients with kidney failure. Akela Pharma's subsidiary PharmaForm provides contract drug development services and specializes in controlled-release drug delivery technology.
Akela Pharma Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - Toronto: AKL Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 57 |
Executives
12 executives listed for Akela Pharma Inc.'s Austin , TX location.
| Chairman | Robert Rieder | |
|---|---|---|
| President, CEO, and Director | Gregory McKee | |
| VP Finance | Richard Martin |